Skip to main content
. 2017 May 9;22(7):786–796. doi: 10.1634/theoncologist.2016-0458

Table 1. Summary of outcomes for patients with BRAF‐mutant NSCLC [1, 8–11].

image

a

Comparison shown for patients with stage IIIb/IV disease only.

b

Activating mutations only.

c

PFS from first‐line therapy.

Abbreviations: —, no data; ALK, anaplastic lymphoma kinase; BRAF, B‐Raf proto‐oncogene, serine/threonine kinase; DFS, disease‐free survival; EGFR, epidermal growth factor receptor; KRAS, KRAS proto‐oncogene, GTPase; NR, not reached; NSCLC, non‐small cell lung cancer; OS, overall survival; PFS, progression‐free survival; V600E, valine at codon 600.